AGMB 447
Alternative Names: AGMB-447; ORG-447Latest Information Update: 12 Jun 2024
At a glance
- Originator Origo Biopharma
- Developer AgomAb Therapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 06 Jun 2024 AGMB 447 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
- 14 Dec 2023 Phase-I clinical trials in Idiopathic pulmonary fibrosis in United Kingdom (Inhalation)
- 01 Dec 2023 Agomab Therapeutics initiates a phase I trial for Idiopathic pulmonary fibrosis in the United Kingdom (NCT06181370)